RxDoctor Payments Data

Komal Akhtar, MD

Hematology & Oncology · Syracuse, NYNPI 1720460801

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $145 of the $225 with a category attached, or 64.4%. It is spread thinly across 8 manufacturers, the largest accounting for just 23.7%. 2025 is the largest year on record at $114, 4.2 times the $27 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.

$225in general payments, 2019–2025

Across 9 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$53
  • Johnson & Johnson$33
  • Pfizer$33
  • E.r. Squibb & Sons, L.L.C.$27
  • AbbVie$21
  • Jazz Pharmaceuticals Inc.$20
  • plus $38 from 2 others
$44,297in research payments, 2019–2025

Across 3 payments — averaging $14,766 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$44K

What the payments were for

  • Food & beverage$14564%
  • Education$8036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$225 in reported general payments places this provider in the 20th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024
$68,484
Medicare patients
209
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Syracuse

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →